INVESTORS

We welcome you to Sofwave’s Investor Relations page and would like to thank you for your interest in our company. Through this page you can find comprehensive and detailed information about our company and the performance of Sofwave.

The information on this page website is especially tailored for institutional investors, analysts and private shareholders as well as anyone interested in Sofwave’s performance.

Presentations

1H 2022 Earning Call
Video: Sofwave's 1H 2022 Earning Call

Sofwave™ Medical LTD reports financial results for the period of January – June 2022 (H1/2022) with accelerated growth in revenues and gross margin. The first half of 2022 revenues reached $13.7 million, an increase of 34% YoY growth, and $2.9 million in recurring revenue from our pulse sales, representing 202% YoY growth. This increase was primarily attributed to the continued marketing and sales investments in the Company’s primary markets and increased demand for the Company’s solutions. To learn more, please watch the video.

Goldberg Webinar
Video: Sofwave™ Investor Webinar with Dr. Goldberg

This exclusive webinar brings together our Sofwave™ management and investors with Dr. David Goldberg to discuss our unique technology, FDA indications, practice ROI and compares our proprietary SUPERB™ technology with existing treatments in the market.

Please note that the following webinar is in both Hebrew and English.

Earning Call 2021
Video: 2021 Earning Call Highlights

Sofwave™ Medical LTD reports financial results for the full year 2021 with accelerated growth in revenues and gross margin. 2021 revenues reached $21.8 million, an increase of 408% compared to 2020. This increase was primarily attributed to the continued marketing and sales investments in the Company’s primary markets and increased demand for the Company’s solutions. To learn more please watch the video.

Sofwave investors H1 Earnings Call
Video: Investor Presentation

This presentation contains forward-looking statements, reflecting Sofwave’s current expectations regarding future events. These statements involve risks and uncertainties. Actual events could differ materially from those projected herein and depend on a number of factors, including the successful and timely completion and the commercialization of the products herein.

Press Releases

November 8, 2022
Sofwave Medical Reports Third Quarter 2022 Financial Results and Business Highlights
Read the full article
November 6, 2022
Sofwave Gains Pre-Market Approval For SUPERB™ Non-Invasive Wrinkle Reduction Technology in Brazil
Read the full article
October 19, 2022
Sofwave™ Granted U.S. Patent Covering Key Elements of the Company’s Proprietary SUPERB™ Non-Surgical Skin and Collagen Remodeling Technology
Read the full article
Aug 17, 2022
Sofwave Medical Reports First Half Financial Results and Business Highlights
Read the full article
Aug 9, 2022
Key Collaboration and Distribution Agreement Signed With Major Partner To Advance Sofwave™ Sales In China’s Growing $29 Billion Aesthetic Medicine Market
Read the full article
May 25, 2022
The medical aesthetic company provides voluntary data for the first quarter of 2022
Read the full article
May 17, 2022
Sofwave™ Technology Wins Major Beauty Awards – 2022 Adding To The 2021 Elle Award
Read the full article
Apr 26, 2022
SOFWAVE™ Is This Year’s NewBeauty Award Winner!
Read the full article
March 10, 2022
Sofwave Medical LTD reports financial results for the full year 2021 with accelerated growth in revenues and gross margin
Read the full article
December 12, 2021
Sofwave™ Awarded ELLE Magazine’s 2021 Future of Beauty Awards!
Read the full article
November 16, 2021
Sofwave™ Announces FDA clearance of New Lifting Indications for Eyebrow, Sub-Mental (beneath the chin) and Neck Facial Areas
Read the full article
September 9, 2021
Sofwave Medical Appoints Assaf Korner as Chief Financial Officer
Read the full article
September 5, 2021
Dr. Glynis Ablon Announces Top Trending Fine Lines and Wrinkle Reduction Treatment Now Offered at Ablon Skin Institute
Read the full article
August 30, 2021
Approval to Market Sofwave™ in South Korea
Read the full article
June 30, 2021
Sofwave™ Medical Raises $50M and Completes Initial Public Offering on the Tel Aviv Stock Exchange
Read the full article
April 20, 2021
Sofwave Receives Australian Regulatory Approval to Market SUPERB™, the Breakthrough Ultrasound Technology Treating Fine Lines & Wrinkles
Read the full article
March 2, 2021
Game-Changing Wrinkle Reduction Device Receives Key Regulatory Clearance in Canada
Read the full article

Sofwave Company Profile

Commitment & Passion

Commitment & Passion

Driven by experience and passion, Sofwave Medical is a fast-growing medical aesthetic technology innovator committed to developing cutting-edge technologies for the global aesthetic market.

Game-Changing Approach

Game-Changing Approach

Sofwave Medical’s breakthrough technology brings a new standard of care to aesthetic treatments, providing physicians with smart yet simple, effective and safe aesthetic treatments for their patients.

Heritage of Innovation

Heritage of Innovation

From key founders of the aesthetic industry, Sofwave Medical brings a novel approach to non-invasive skin treatments using proprietary Synchronous Ultrasound Parallel Beam Technology SUPERB™.

Sofwave TM Medical Completes Initial Public Offering on the Tel Aviv Stock Exchange
Video: Sofwave™ Mode of Action

Management

Dr. Shimon EckhouseRead More
Dr. Shimon Eckhouse
Chairman & Co-Founder
Louis ScafuriRead More
Louis Scafuri
CEO
Assaf KorenRead More
Assaf Korner
CFO
Genady NahshonRead More
Genady Nahshon
COO & Site Manager
Dr Ruthi AmirRead More
Dr. Ruthie Amir
Chief Medical Officer
Lina OmariRead More
Lina Omari
Chief Digital Officer
Ariel SverdlikRead More
Ariel Sverdlik
Co-Founder and CTO

    Contact Us

    Fill out the form below and we will reach out to you.

    © 2022 Sofwave TM